{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:22:00Z","timestamp":1778595720004,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009665","name":"Vehicle Racing Commemorative Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004043","name":"Kanazawa Medical University","doi-asserted-by":"publisher","award":["C2011-3"],"award-info":[{"award-number":["C2011-3"]}],"id":[{"id":"10.13039\/501100004043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001863","name":"New Energy and Industrial Technology Development Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001863","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.dmpk.2019.08.004","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T12:56:45Z","timestamp":1567083405000},"page":"387-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients"],"prefix":"10.1016","volume":"34","author":[{"given":"Nora","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Fukizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Ieiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Tomaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Akao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Iwadare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tougen","family":"Masauji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoe","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Kajinami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dmpk.2019.08.004_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cts.12390","article-title":"Microdosing and other phase 0 clinical Trials: facilitating translation in drug development","volume":"9","author":"Burt","year":"2016","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.dmpk.2019.08.004_bib2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.addr.2011.02.004","article-title":"Novel strategies for microdose studies using non-radiolabeled compounds","volume":"63","author":"Maeda","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.dmpk.2019.08.004_bib3","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1177\/0091270011408612","article-title":"Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose","volume":"52","author":"Ieiri","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2019.08.004_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.dmpk.2017.09.003","article-title":"Comparison of pharmacokinetics of newly discovered aromatase inhibitors by a cassette microdosing approach in healthy Japanese subjects","volume":"32","author":"Kusuhara","year":"2017","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmpk.2019.08.004_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/cpt.525","article-title":"Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A","volume":"101","author":"Prueksaritanont","year":"2017","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.dmpk.2019.08.004_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jpba.2018.02.063","article-title":"Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening","volume":"154","author":"Xiao","year":"2018","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"9","key":"10.1016\/j.dmpk.2019.08.004_bib7","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1002\/jps.24499","article-title":"An assessment of the oral bioavailability of three Ca-channel blockers using a cassette-microdose study: a new strategy for streamlining oral drug development","volume":"104","author":"Yamashita","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"4","key":"10.1016\/j.dmpk.2019.08.004_bib8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00280-015-2844-2","article-title":"A\u00a0clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer","volume":"76","author":"Fujita","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.dmpk.2019.08.004_bib9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0002-9343(01)00870-1","article-title":"Clinically relevant differences between the statins: implications for therapeutic selection","volume":"111","author":"Chong","year":"2001","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.dmpk.2019.08.004_bib10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2165\/00003495-199753050-00011","article-title":"Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias","volume":"53","author":"Lea","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.dmpk.2019.08.004_bib11","first-page":"062","article-title":"Analytes of interest and choice of dose: two important considerations in the design of bioequivalence studies with atorvastatin","volume":"3","author":"Gandelman","year":"2011","journal-title":"J\u00a0Bioequiv Availab"},{"issue":"5","key":"10.1016\/j.dmpk.2019.08.004_bib12","first-page":"967","article-title":"Pharmacokinetics of atorvastatin and its metabolites after single and multiple\u00a0dosing in hypercholesterolaemic haemodialysis patients","volume":"18","author":"Lins","year":"2003","journal-title":"Nephrol Dial\u00a0Transplant \u2013 Off Publ Eur Dial Transplant Assoc \u2013 Eur Renal Assoc"},{"issue":"2","key":"10.1016\/j.dmpk.2019.08.004_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.taap.2013.03.019","article-title":"ATP-dependent transport of statins by human and rat MRP2\/Mrp2","volume":"269","author":"Ellis","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2019.08.004_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clpt.2006.09.010","article-title":"Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart","volume":"80","author":"Grube","year":"2006","journal-title":"Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.dmpk.2019.08.004_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.114.059105","article-title":"Investigation of the impact of substrate selection on in\u00a0vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions","volume":"43","author":"Izumi","year":"2015","journal-title":"Drug Metab Dispos: Biol Fate Chem"},{"issue":"2","key":"10.1016\/j.dmpk.2019.08.004_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11095-011-0564-9","article-title":"In\u00a0vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions","volume":"29","author":"Karlgren","year":"2012","journal-title":"Pharm Res"},{"issue":"10","key":"10.1016\/j.dmpk.2019.08.004_bib17","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.dmpk.2019.08.004_bib18","first-page":"244","article-title":"Prediction of the in\u00a0vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins","volume":"47","author":"Sharma","year":"2012","journal-title":"Eur J Pharm Sci \u2013 Off J Eur Fed Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmpk.2019.08.004_bib19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11095-011-0579-2","article-title":"Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in\u00a0vitro Km values","volume":"29","author":"Tachibana","year":"2012","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.dmpk.2019.08.004_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/clpt.2011.142","article-title":"Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study","volume":"90","author":"Maeda","year":"2011","journal-title":"Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2019.08.004_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00228-014-1801-z","article-title":"Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.dmpk.2019.08.004_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cca.2009.04.003","article-title":"Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism","volume":"405","author":"He","year":"2009","journal-title":"Clin Chim Acta Int J Clin Chem"},{"issue":"4","key":"10.1016\/j.dmpk.2019.08.004_bib23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/clpt.2008.74","article-title":"Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism","volume":"84","author":"Kalliokoski","year":"2008","journal-title":"Clin Pharm Ther"},{"issue":"6","key":"10.1016\/j.dmpk.2019.08.004_bib24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharm Ther"},{"issue":"4","key":"10.1016\/j.dmpk.2019.08.004_bib25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"DeGorter","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"issue":"2","key":"10.1016\/j.dmpk.2019.08.004_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.dmpk.2019.08.004_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.5551\/jat.17152","article-title":"Diagnostic criteria for dyslipidemia","volume":"20","author":"Teramoto","year":"2013","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"1","key":"10.1016\/j.dmpk.2019.08.004_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.104.001628","article-title":"Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta","volume":"33","author":"Kobayashi","year":"2005","journal-title":"Drug Metab Dispos: Biol Fate Chem"},{"issue":"6","key":"10.1016\/j.dmpk.2019.08.004_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0009-9236(03)00060-2","article-title":"Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics","volume":"73","author":"Nishizato","year":"2003","journal-title":"Clin Pharm Ther"},{"issue":"5","key":"10.1016\/j.dmpk.2019.08.004_bib30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1023\/A:1023294632129","article-title":"Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method","volume":"26","author":"Hisaka","year":"1998","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"issue":"10","key":"10.1016\/j.dmpk.2019.08.004_bib31","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1124\/dmd.108.021410","article-title":"Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin","volume":"36","author":"Kitamura","year":"2008","journal-title":"Drug Metab Dispos: Biol Fate Chem"},{"issue":"6","key":"10.1016\/j.dmpk.2019.08.004_bib32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1476-5381.2012.01887.x","article-title":"Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in\u00a0vivo inhibitor of BCRP","volume":"166","author":"Kusuhara","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2019.08.004_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/dmd.109.030254","article-title":"Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans","volume":"38","author":"Watanabe","year":"2010","journal-title":"Drug Metab Dispos: Biol Fate Chem"},{"issue":"3","key":"10.1016\/j.dmpk.2019.08.004_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"International Transporter","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.dmpk.2019.08.004_bib35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1248\/bpb.b14-00767","article-title":"Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs","volume":"38","author":"Maeda","year":"2015","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/j.dmpk.2019.08.004_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/14622416.9.1.19","article-title":"Global analysis of genetic variation in SLCO1B1","volume":"9","author":"Pasanen","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"11","key":"10.1016\/j.dmpk.2019.08.004_bib37","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0090-9556(24)15086-6","article-title":"Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin","volume":"28","author":"Jacobsen","year":"2000","journal-title":"Drug Metab Dispos: Biol Fate Chem"},{"issue":"12","key":"10.1016\/j.dmpk.2019.08.004_bib38","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1124\/dmd.110.034140","article-title":"CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs","volume":"38","author":"Maekawa","year":"2010","journal-title":"Drug Metab Dispos: Biol Fate Chem"},{"issue":"9","key":"10.1016\/j.dmpk.2019.08.004_bib39","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/00498250802334391","article-title":"Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin","volume":"38","author":"Park","year":"2008","journal-title":"Xenobiotica Fate Foreign Comp Biol Syst"},{"issue":"5","key":"10.1016\/j.dmpk.2019.08.004_bib40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/FPC.0b013e3282f974dc","article-title":"Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in\u00a0vivo probe","volume":"18","author":"Urquhart","year":"2008","journal-title":"Pharmacogenetics Genom"},{"issue":"1\u20132","key":"10.1016\/j.dmpk.2019.08.004_bib41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2006.05.010","article-title":"Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males","volume":"373","author":"Zhang","year":"2006","journal-title":"Clin Chim Acta Int J Clin Chem"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436719300680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436719300680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:01:14Z","timestamp":1778594474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436719300680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1347436719300680"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2019.08.004","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2019.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}